AU2018249552A1 - Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety - Google Patents
Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety Download PDFInfo
- Publication number
- AU2018249552A1 AU2018249552A1 AU2018249552A AU2018249552A AU2018249552A1 AU 2018249552 A1 AU2018249552 A1 AU 2018249552A1 AU 2018249552 A AU2018249552 A AU 2018249552A AU 2018249552 A AU2018249552 A AU 2018249552A AU 2018249552 A1 AU2018249552 A1 AU 2018249552A1
- Authority
- AU
- Australia
- Prior art keywords
- antimicrobial
- pharmaceutical composition
- synthetic cationic
- antimicrobial pharmaceutical
- cationic polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000002091 cationic group Chemical group 0.000 title claims abstract description 281
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 276
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 276
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 276
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 248
- 239000000203 mixture Substances 0.000 title description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 153
- 238000000034 method Methods 0.000 claims abstract description 79
- 230000000813 microbial effect Effects 0.000 claims abstract description 59
- 239000008365 aqueous carrier Substances 0.000 claims abstract description 51
- 239000004599 antimicrobial Substances 0.000 claims abstract description 45
- 238000011109 contamination Methods 0.000 claims abstract description 22
- 230000036074 healthy skin Effects 0.000 claims abstract description 13
- 230000007935 neutral effect Effects 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 109
- 210000001519 tissue Anatomy 0.000 claims description 82
- 230000001954 sterilising effect Effects 0.000 claims description 80
- 238000004659 sterilization and disinfection Methods 0.000 claims description 80
- 230000002209 hydrophobic effect Effects 0.000 claims description 64
- 239000000654 additive Substances 0.000 claims description 43
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 41
- 230000000996 additive effect Effects 0.000 claims description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 238000001338 self-assembly Methods 0.000 claims description 29
- 230000007423 decrease Effects 0.000 claims description 25
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 24
- 230000003641 microbiacidal effect Effects 0.000 claims description 21
- 241000699670 Mus sp. Species 0.000 claims description 18
- 230000015227 regulation of liquid surface tension Effects 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 16
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 13
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000811 xylitol Substances 0.000 claims description 13
- 235000010447 xylitol Nutrition 0.000 claims description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 13
- 229960002675 xylitol Drugs 0.000 claims description 13
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 230000002776 aggregation Effects 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 238000010610 time kill assay Methods 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
- 229930195725 Mannitol Natural products 0.000 claims description 9
- 239000000017 hydrogel Substances 0.000 claims description 9
- 239000000594 mannitol Substances 0.000 claims description 9
- 235000010355 mannitol Nutrition 0.000 claims description 9
- 108010088751 Albumins Proteins 0.000 claims description 8
- 102000009027 Albumins Human genes 0.000 claims description 8
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 231100000053 low toxicity Toxicity 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960001340 histamine Drugs 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000001603 reducing effect Effects 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 210000001635 urinary tract Anatomy 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 68
- 231100000419 toxicity Toxicity 0.000 abstract description 18
- 230000001988 toxicity Effects 0.000 abstract description 18
- 238000002360 preparation method Methods 0.000 description 81
- 206010052428 Wound Diseases 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- 229960003136 leucine Drugs 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 34
- 208000027418 Wounds and injury Diseases 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 238000011081 inoculation Methods 0.000 description 22
- 229920000642 polymer Polymers 0.000 description 21
- 235000002639 sodium chloride Nutrition 0.000 description 21
- 231100000057 systemic toxicity Toxicity 0.000 description 21
- 238000013461 design Methods 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 18
- 235000018977 lysine Nutrition 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 230000009885 systemic effect Effects 0.000 description 17
- 239000004395 L-leucine Substances 0.000 description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 16
- 239000004472 Lysine Substances 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 238000007912 intraperitoneal administration Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 16
- 238000001542 size-exclusion chromatography Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 230000004888 barrier function Effects 0.000 description 13
- -1 cationic amino acid Chemical class 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 235000019454 L-leucine Nutrition 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 241000283984 Rodentia Species 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 9
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 238000012423 maintenance Methods 0.000 description 8
- 230000001991 pathophysiological effect Effects 0.000 description 8
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229920002413 Polyhexanide Polymers 0.000 description 3
- 108010039918 Polylysine Proteins 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003214 anti-biofilm Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000009878 intermolecular interaction Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920000656 polylysine Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 206010009137 Chronic sinusitis Diseases 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010058667 Oral toxicity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 238000002802 antimicrobial activity assay Methods 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000032770 biofilm formation Effects 0.000 description 2
- 108010068385 carbapenemase Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 231100000418 oral toxicity Toxicity 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 231100000155 toxicity by organ Toxicity 0.000 description 2
- 230000007675 toxicity by organ Effects 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 206010060968 Arthritis infective Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010064687 Device related infection Diseases 0.000 description 1
- 101100411608 Dictyostelium discoideum racL gene Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 102000004187 Histamine H4 receptors Human genes 0.000 description 1
- 108090000796 Histamine H4 receptors Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 150000008544 L-leucines Chemical class 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000034809 Product contamination Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 150000004287 bisbiguanides Chemical class 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001225 mammalian toxicity Toxicity 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000002669 organ and tissue protective effect Effects 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- 238000000196 viscometry Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Surgery (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023202283A AU2023202283A1 (en) | 2017-04-06 | 2023-04-13 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482630P | 2017-04-06 | 2017-04-06 | |
| US62/482,630 | 2017-04-06 | ||
| PCT/US2018/026322 WO2018187617A1 (en) | 2017-04-06 | 2018-04-05 | Compositions and uses of locally applied antimicrobials with enhanced performance and safety |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023202283A Division AU2023202283A1 (en) | 2017-04-06 | 2023-04-13 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018249552A1 true AU2018249552A1 (en) | 2019-10-31 |
Family
ID=63712780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018249552A Abandoned AU2018249552A1 (en) | 2017-04-06 | 2018-04-05 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
| AU2023202283A Pending AU2023202283A1 (en) | 2017-04-06 | 2023-04-13 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023202283A Pending AU2023202283A1 (en) | 2017-04-06 | 2023-04-13 | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11285189B2 (https=) |
| EP (1) | EP3606543A4 (https=) |
| JP (3) | JP2020513016A (https=) |
| KR (2) | KR20200018400A (https=) |
| CN (1) | CN110740744A (https=) |
| AU (2) | AU2018249552A1 (https=) |
| BR (1) | BR112019020781A2 (https=) |
| CA (1) | CA3058901C (https=) |
| MX (2) | MX393548B (https=) |
| SG (1) | SG11201909016TA (https=) |
| WO (1) | WO2018187617A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991989T3 (es) | 2012-03-23 | 2024-12-05 | Macro Biologics Inc | Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos |
| US11285189B2 (en) | 2017-04-06 | 2022-03-29 | Amicrobe, Inc. | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
| JP2023501385A (ja) | 2019-11-08 | 2023-01-18 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 抗微生物ペプチドを含む組成物 |
| WO2021202577A1 (en) * | 2020-03-31 | 2021-10-07 | 3-D Matrix, Ltd. | Sterilization of self-assembling peptides by irradiation |
| US20230149333A1 (en) * | 2020-04-08 | 2023-05-18 | Amicrobe, Inc. | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections |
| US12371463B2 (en) | 2021-04-20 | 2025-07-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods and compositions for treatment of antibiotic-resistant bacterial infections |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5636643A (en) | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6680365B1 (en) | 1998-03-19 | 2004-01-20 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| TW570805B (en) | 1998-09-01 | 2004-01-11 | Hoffmann La Roche | Water-soluble pharmaceutical composition in an ionic complex |
| US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| MXPA03002640A (es) | 2000-09-28 | 2003-06-19 | Chiron Corp | Microparticulas para la distribucion de acidos nucleicos heterologos. |
| US6835536B2 (en) | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| JP2003171463A (ja) * | 2001-12-06 | 2003-06-20 | Chisso Corp | ポリリジン及びその製造法 |
| CA2443472A1 (en) | 2002-02-07 | 2003-08-14 | Ophtecs Corporation | Liquid formulation for contact lenses |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| EP1644382B1 (en) | 2003-07-11 | 2008-03-05 | Theravance, Inc. | Cross-linked glycopeptide-cephalosporin antibiotics |
| WO2005018701A1 (en) | 2003-08-25 | 2005-03-03 | Kane Biotech Inc. | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation |
| WO2005063278A1 (en) | 2003-12-30 | 2005-07-14 | Bioactive Polymers Ab | Surface protection of exposed biological tissues |
| ATE381945T1 (de) * | 2004-03-12 | 2008-01-15 | Intercell Ag | Verfahren zur solubilisierung von peptid- mischungen |
| PL1778720T3 (pl) | 2004-08-18 | 2011-03-31 | Novabiotics Ltd | Antybakteryjne peptydy zawierające wzór zawierający argininę i/lub lizynę |
| EP1891097B1 (en) | 2005-06-06 | 2016-11-16 | Adenium Biotech ApS | Polypeptides having antimicrobial activity and polynucleotides encoding same |
| US20080139450A1 (en) | 2005-07-01 | 2008-06-12 | Srinivasa Madhyastha | Antimicrobial Compositions and Uses Thereof |
| US20070190110A1 (en) | 2006-02-10 | 2007-08-16 | Pameijer Cornelis H | Agents and devices for providing blood clotting functions to wounds |
| CA2671461C (en) | 2006-12-01 | 2014-01-28 | The Regents Of The University Of California | Vesicles of self-assembling block copolymers and methods for making and using the same |
| CN101720237A (zh) | 2007-06-25 | 2010-06-02 | 利波佩普蒂德有限公司 | 新型医用产品 |
| WO2009032605A2 (en) | 2007-08-27 | 2009-03-12 | Massachusetts Institute Of Technology | Bi-functional polymer-attached inhibitors of influenza virus |
| KR20110031168A (ko) | 2008-06-19 | 2011-03-24 | 니뽄 신야쿠 가부시키가이샤 | 약물 담체 |
| CN102256613B (zh) | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| WO2010083589A1 (en) | 2009-01-23 | 2010-07-29 | Kane Biotech Inc. | Biofilm-removing antimicrobial compositions and uses thereof |
| GB0905451D0 (en) | 2009-03-31 | 2009-05-13 | Novabiotics Ltd | Biofilms |
| SG184836A1 (en) | 2010-04-27 | 2012-11-29 | Lysando Ag | Method of reducing biofilms |
| SG188281A1 (en) | 2010-08-23 | 2013-04-30 | Univ California | Compositions and uses of materials with high antimicrobial activity and low toxicity |
| JP5613779B2 (ja) * | 2011-01-19 | 2014-10-29 | 株式会社メニコン | コンタクトレンズ用液剤 |
| US9781949B2 (en) | 2011-03-31 | 2017-10-10 | The University Of Massachusetts | Antimicrobial delivery systems, methods of manufacture, and methods of use thereof |
| ES2991989T3 (es) | 2012-03-23 | 2024-12-05 | Macro Biologics Inc | Composiciones y usos de materiales antimicrobianos con propiedades compatibles con tejidos |
| DE102014101663A1 (de) | 2014-02-11 | 2015-08-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Synthetische artifizielle Peptide mit antimikrobieller Wirkung |
| WO2016044683A1 (en) | 2014-09-19 | 2016-03-24 | Tensive Controls, Inc. | Anti-microbial peptides |
| EP3215126A1 (en) | 2014-10-30 | 2017-09-13 | Biomet Manufacturing, LLC | Methods of preventing surgical site infections |
| JP2016113373A (ja) * | 2014-12-11 | 2016-06-23 | エスポ化学株式会社 | 抗菌性、抗ウイルス性を有する水溶性組成物 |
| US11285189B2 (en) | 2017-04-06 | 2022-03-29 | Amicrobe, Inc. | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety |
| US20210007999A1 (en) | 2018-03-02 | 2021-01-14 | January Therapeutics, Inc. | Nanoparticle compositions |
-
2018
- 2018-04-05 US US16/500,288 patent/US11285189B2/en active Active
- 2018-04-05 CN CN201880037998.9A patent/CN110740744A/zh active Pending
- 2018-04-05 KR KR1020197032623A patent/KR20200018400A/ko not_active Ceased
- 2018-04-05 WO PCT/US2018/026322 patent/WO2018187617A1/en not_active Ceased
- 2018-04-05 EP EP18780547.8A patent/EP3606543A4/en active Pending
- 2018-04-05 KR KR1020247029282A patent/KR20240135875A/ko not_active Ceased
- 2018-04-05 JP JP2019554855A patent/JP2020513016A/ja active Pending
- 2018-04-05 MX MX2019011912A patent/MX393548B/es unknown
- 2018-04-05 SG SG11201909016T patent/SG11201909016TA/en unknown
- 2018-04-05 AU AU2018249552A patent/AU2018249552A1/en not_active Abandoned
- 2018-04-05 BR BR112019020781A patent/BR112019020781A2/pt unknown
- 2018-04-05 CA CA3058901A patent/CA3058901C/en active Active
-
2019
- 2019-10-03 MX MX2022007904A patent/MX2022007904A/es unknown
-
2022
- 2022-03-08 US US17/654,021 patent/US12268722B2/en active Active
-
2023
- 2023-02-27 JP JP2023028902A patent/JP7656643B2/ja active Active
- 2023-04-13 AU AU2023202283A patent/AU2023202283A1/en active Pending
-
2025
- 2025-03-24 JP JP2025049135A patent/JP2025090864A/ja active Pending
- 2025-03-25 US US19/090,034 patent/US20260041728A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240135875A (ko) | 2024-09-12 |
| JP7656643B2 (ja) | 2025-04-03 |
| MX393548B (es) | 2025-03-24 |
| CN110740744A (zh) | 2020-01-31 |
| WO2018187617A8 (en) | 2019-10-17 |
| CA3058901C (en) | 2025-05-06 |
| WO2018187617A1 (en) | 2018-10-11 |
| EP3606543A1 (en) | 2020-02-12 |
| JP2020513016A (ja) | 2020-04-30 |
| AU2023202283A1 (en) | 2023-05-11 |
| CA3058901A1 (en) | 2018-10-11 |
| JP2023054375A (ja) | 2023-04-13 |
| KR20200018400A (ko) | 2020-02-19 |
| JP2025090864A (ja) | 2025-06-17 |
| US11285189B2 (en) | 2022-03-29 |
| RU2019133628A3 (https=) | 2021-07-14 |
| US12268722B2 (en) | 2025-04-08 |
| EP3606543A4 (en) | 2020-12-16 |
| RU2019133628A (ru) | 2021-05-06 |
| US20210100867A1 (en) | 2021-04-08 |
| US20260041728A1 (en) | 2026-02-12 |
| US20230017994A1 (en) | 2023-01-19 |
| SG11201909016TA (en) | 2019-10-30 |
| BR112019020781A2 (pt) | 2020-04-28 |
| MX2022007904A (es) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12268722B2 (en) | Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety | |
| Nguyen et al. | Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment | |
| Almeida et al. | Pluronic® F-127 and Pluronic Lecithin Organogel (PLO): Main features and their applications in topical and transdermal administration of drugs | |
| JP5203472B2 (ja) | キサンタンガムを含む再上皮化医薬組成物 | |
| KR102266659B1 (ko) | 조직-적합성 특성을 갖는 항균물질의 조성물 및 용도 | |
| Das et al. | The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle | |
| EP4384229A1 (en) | Films formed from self-assembling peptide hydrogels | |
| CN105744929A (zh) | 由透明质酸制成的连续释放组合物及其治疗应用 | |
| Nnamani et al. | Evaluation of Hydrogels Based on Poloxamer 407 and Polyacrylic Acids for Enhanced Topical Activity of Gentamicin against Susceptible Infections. | |
| CZ20032771A3 (cs) | Farmaceutická kompozice na bázi makrolidů pro lokální podání v očním lékařství | |
| CN109568645B (zh) | 一种复合生长因子促修复凝胶及其制备方法与应用 | |
| Sha et al. | In situ gels: The next new frontier in ophthalmic drug delivery system | |
| RU2824578C2 (ru) | Композиции и применения антимикробных средств для местного применения с улучшенными характеристиками и безопасностью | |
| Mao et al. | A review on in situ gels as polymer drug carriers in the treatment of periodontitis | |
| KR20200080493A (ko) | 효과 지속성 점안제 조성물 | |
| WO2019084197A1 (en) | DEGRADABLE HYDROGELS SENSITIVE TO TEMPERATURE | |
| P Venkatesh et al. | In situ gels based drug delivery systems | |
| TW201628657A (zh) | 眼用組成物 | |
| EP4356929A1 (en) | Antifibrotic formulation for ophthalmic treatment | |
| WO2026060306A1 (en) | Compositions and uses of locally applied synthetic cationic and hydrophobic amino acid block copolymers, for prevention and treatment of bacterial and fungal infections | |
| US20230149333A1 (en) | Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS AND USES OF LOCALLY-APPLIED ANTIMICROBIAL SYNTHETIC CATIONIC POLYPEPTIDE(S) WITH ENHANCED PERFORMANCE AND SAFETY |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |